Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Brain dopamine dysfunction in attention deficit/hyperactivity disorder (ADHD) could explain why stimulant medications, which increase dopamine signaling, are therapeutically beneficial. However while the acute increases in dopamine induced by stimulant medications have been associated with symptom improvement in ADHD the chronic effects have not been investigated. METHOD: We used positron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 never-medicated adult ADHD subjects prior to and after 12 months of treatment with methylphenidate and in 11 controls who were also scanned twice at 12 months interval but without stimulant medication. Dopamine transporter availability was quantified as non-displaceable binding potential using a kinetic model for reversible ligands. RESULTS: Twelve months of methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, putamen and ventral striatum: +24%, p<0.01); whereas there were no changes in control subjects retested at 12-month interval. Comparisons between controls and ADHD participants revealed no significant difference in dopamine transporter availability prior to treatment but showed higher dopamine transporter availability in ADHD participants than control after long-term treatment (caudate: p<0.007; putamen: p<0.005). CONCLUSION: Upregulation of dopamine transporter availability during long-term treatment with methylphenidate may decrease treatment efficacy and exacerbate symptoms while not under the effects of the medication. Our findings also suggest that the discrepancies in the literature regarding dopamine transporter availability in ADHD participants (some studies reporting increases, other no changes and other decreases) may reflect, in part, differences in treatment histories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“research has shown that chronic MPH application is able to upregulate striatal dopamine turnover (Wang et al., 2013).”
From Differentiating neural reward responsiveness in autism versus ADHD (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In another study, in adults with ADHD, long-term MPH treatment increased striatal DAT availability (216).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationVolkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationEvaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728 · cited 1×
“Full characteristics of the subjects have been described previously [5], so only a summary will be presented here.”
BackgroundSelf-citationdel Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
(2012) · PubMed · Cited by 526
Self-citationVolkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Self-citationKuczenski, R., & Segal, D. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07264.2002 · Cited by 316 · cited 1×
“Indeed, studies on the chronic effects of MPH have reported conflicting results with some documenting sensitization to the locomotor effects of MPH [21], others tolerance [22], and others no changes [23].”
BackgroundZahniser, N. R., & Doolen, S. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00158-9 · Cited by 310
Research works printed but not linked: 2
- Conners CK (1998) Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 59 Suppl 7: 24– 30. 9680050
- Volkow ND, Wang GJ, Tomasi D, Kollins S, Wigal T, et al (2013) Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with ADHD. Journal of neuroscience In press. PMC3350870 22262882
Cited by
Items 101–175 of 175
Chuang, W. C., Yeh, C. B., Huang, W. S., Gau, S. S., Shyu, J. F., & Ma, K. H. (2017) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000244 · Cited by 6
Sian‐Hülsmann, J., Knudsen, L. V., Sheldrick, A. J., Riederer, P., & Michel, T. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-025-03078-9 · Cited by 5
Tout ce que vous devez connaître sur le méthylphénidate (sans oser le demander…)
Zimmer, L., & Fourneret, P. (2018) · Archives de Pédiatrie · doi:10.1016/j.arcped.2018.01.002 · Cited by 5
Bogdańska-Chomczyk, E., Rowniak, M., Wojtacha, P., Tsai, M. L., Huang, A. C. W., & Kozłowska, A. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1414457 · Cited by 5
Cortese, S., Besag, F., Clark, B., Hollis, C. P., Kilgariff, J., Moreno, C., Nicholls, D., Wilkinson, P. O., Woodbury‐Smith, M., & Sharma, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140005 · Cited by 5
Candidate mechanisms of caffeine improving memory dysfunction
Alhowail, A. (2019) · Die Pharmazie · doi:10.31083/ph.2019.9711 · Cited by 5
Souza, T. K. N., da Silva, M. F., Alves, R. M. B., & Moura, W. S. (2022) · iSys - Brazilian Journal of Information Systems · doi:10.5753/isys.2022.2235 · Cited by 5
Zhang, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1100008 · Cited by 4
Neurodevelopmental Disorders: Attention‐Deficit/Hyperactivity Disorder
Newcorn, J. H., Leikauf, J. E., Johnson, B., Krone, B., & Halperin, J. M. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch45 · Cited by 4
Self-citationYates, J. R., Broderick, M. R., Berling, K. L., Gieske, M. G., Osborn, E., Nelson, M. R., & Wright, M. R. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110970 · Cited by 3
Novel Ways of Targeting the Dopamine Transporter
Xu, Y., Zeng, H., Aggarwal, S., & Mortensen, O. V. (2025) · Advances in neurobiology · doi:10.1007/978-3-031-96364-3_11 · Cited by 3
Collins, P. A. W. (2016) · Nottingham ePrints (University of Nottingham) · Cited by 3
Visual processing oscillates differently through time for adults with ADHD
Pelland-Goulet, P., Arguin, M., Brisebois, H., & Gosselin, N. H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0310605 · Cited by 2
АНАЛІЗ ПСИХОЛОГІЧНИХ МЕТОДІВ ДИФЕРЕНЦІАЛЬНОЇ ДІАГНОСТИКИ РДУГ У ДИТЯЧОМУ ВІЦІ
Rudenko, L. M. (2024) · Науковий часопис НПУ імені М П Драгоманова Серія 12 Психологічні науки · doi:10.31392/udu-nc.series12.2024.23(68).11 · Cited by 2
Adult ADHD: Future Directions for Practice and Research
Pallanti, S., & Salerno, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-39051-8_20 · Cited by 2
May, E. M., Comasco, E., Tiepolt, S., Strauß, M., Kundaković, M., Hesse, S., Sabri, O., Villringer, A., & Sacher, J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.01.021 · Cited by 2
Rosenau, P. T., Dietrich, A., van den Hoofdakker, B. J., & Hoekstra, P. J. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-024-02609-1 · Cited by 2
Lee, H.-J., Jeong, Y. J., Kim, J., Kim, S., Jo, U., Jun, S. J., Lim, J., Park, J., Lee, M., Kim, D. Y., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3633 · Cited by 2
Sánchez, G., & Isabel, C. (2017) · Biblos-e Archivo (Universidad Autónoma de Madrid) · Cited by 2
Rise and Regional Variations in Schedule II Stimulant Use in the United States
.Vaddadi, S. M., Czelatka, N. J., Gutierrez, B. D., Maddineni, B. C., Torres-Teran, C. D., Tron, D. N., McCall, K. L., & Piper, B. J. (2020) · Scholarly Research In Progress · doi:10.64057/001c.142567 · Cited by 2
To Prescribe or Not? Pharmacological Options in Adult Attention-Deficit/Hyperactivity Disorder
Aoshima-Kilroy, A., Banu, S., Udoetuk, S., Shah, A. A., & Moukaddam, N. (2017) · Psychiatric Annals · doi:10.3928/00485713-20170510-01 · Cited by 1
Is er een typisch neuropsychologisch profiel bij volwassenen met ADHD? Een ontwikkelingsperspectief
Tamminga, H. G. H., & Geurts, H. M. (2016) · Neuropraxis · doi:10.1007/s12474-015-0110-3 · Cited by 1
Visuospatial attention and intelligence in children with ADHD-hyperactive type
Smirni, D., Smirni, P., & Roccella, M. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004139 · Cited by 1
Chapitre 2. Modèles et Neurosciences
Gaillac, V., & Vera, L. (2016) · Dunod eBooks · doi:10.3917/dunod.verag.2016.01.0018 · Cited by 1
A comprehensive overview of the biological foundations of ADHD
Folego-Temoteo, I., Lima, Y. C., Grevet, E. H., Vidor, M. V., Tavares, M. E., da Silva, B. S., Bau, C. H. D., & Rovaris, D. L. (2026) · Bioscience Reports · doi:10.1042/bsr20254061 · Cited by 1
Does Early Exposure to Stimulants Lead to Substance Use Disorders Later on?
Prousky, J. E. (2015) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.17.1.22 · Cited by 1
Schmiedeke, D. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8098 · Cited by 1
Neurofeedback using video games for attention-deficit/hyperactivity disorder
Mir, N., Khan, M. A. U., & Ansari, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822060-3.00010-3 · Cited by 1
Downing, V. (2025) · Open University of Cape Town (University of Cape Town) · Cited by 1
Waitt, A. E. (2022) · Nottingham ePrints (University of Nottingham) · Cited by 1
Zhang, D. (2018) · Research Online (University of Wollongong) · Cited by 1
Storying the statistics : a personal perspective on ADHD
Richardson, M. J. (2022) · TSpace (University of Toronto) · Cited by 1
Randomized Control Study of Neurofeedback With College Students With ADHD
Roberts, A. M. (2015) · Scholar Commons (University of South Carolina) · Cited by 1
Altable, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-40858-8_298-1
Validating a novel ADHD model for medication development
Majdak, P. (2016) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Developing multidimensional metrics for evaluating paediatric neurodevelopmental disorders
Nakubulwa, M. A. (2016) · Aston Publications Explorer (Aston University) · doi:10.48780/publications.aston.ac.uk.00028813
Bieś, R., Chabrzyk, A., Zborowska, K., Krysta, K., & Krzystanek, M. (2026) · Pharmaceuticals · doi:10.3390/ph19091409
Emch, M. (2015) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Gill, K. E. (2013) · WakeSpace Scholarship (Wake Forest University)
Editorial: Deciphering dopamine dysregulation in adult ADHD
Yasui‐Furukori, N. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70151
The effects of deep TMS on QEEG power, asymmetry, and coherence metrics in major depressive disorder
Shanok, N. A., Derbin, B., Muzac, S., & Rodriguez, R. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117422
Vansina, E., Douw, L., Kaiser, A., van der Pal, Z., Boucherie, D. E., Vries, T. J. D., Pattij, T., Cohen, J. R., Hoekstra, P. J., Reneman, L., et al. (2025) · medRxiv · doi:10.1101/2025.08.27.25334547
Rubia, K., Johansson, L. C., Carter, B., Stringer, D., Santosh, P., Mehta, M. A., Conti, A. A., Bozhilova, N. S., Eraydin, I. E., & Cortese, S. (2024) · Figshare · doi:10.6084/m9.figshare.26714338
Alves, R. M. B., & da Silva, M. F. (2024) · Simpósio Brasileiro de Sistemas Colaborativos (SBSC) · doi:10.5753/sbsc_estendido.2024.238521
Alves, R. M. B., & da Silva, M. F. (2024) · Anais do Simpósio Brasileiro de Sistemas de Informação (SBSI) · doi:10.5753/sbsi_estendido.2024.238611
Morandini, H. A. E., Schulze, M., Ayton, S., Smirnova, L., Silk, T. J., & Rao, P. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2734624
Methylphenidate-induced changes in target-enriched functional connectivity in ADHDPreprint
van der Pal, Z., Reneman, L., Geurts, H. M., Boucherie, D. E., Douw, L., & Schrantee, A. (2025) · medRxiv · doi:10.1101/2025.11.26.25341066
Changes in Prescription and Illicit Stimulant Use in the United States, 2014 to 2018
Boyle, J. M., Funk, H. E., Pitt, S. E., Varano, A. T., Vaddadi, S., Piper, B. J., & McCall, K. L. (2020) · Scholarly Research In Progress · doi:10.64057/001c.154617
Dervola, K.-S. N. (2015) · NVA (Nasjonalt vitenarkiv)
Die Behandlung von ADHS im Erwachsenenalter mit retardiertem Methylphenidat
Ahlers, E., & Neuhaus, A. (2014) · Die Psychiatrie · doi:10.1055/s-0038-1670753
The Mindful Seon Hwadu: Sisimma as a healing utility; its efficacy for AD/HD and Beyond
CHOI, J. J., & Hyun, C. H. O. O. (2018) · International Journal of Theology Philosophy and Science · doi:10.26520/ijtps.2018.2.3.38-59
Morandini, H. A. E., Vos, S. B., Chivers, P., Silk, T. J., & Rao, P. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150354
Kong, J., Yang, Z., Liu, Y., & Chen, W. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s620247
Exploring prevention strategies and treatment in addictive disorders
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-5978-9
TDAH chez les collégiens : fonctionnement scolaire, cognitif et cérébral
Pelland-Goulet, P. (2026) · doi:10.71781/34285
Reward sensitivity in ADHD: what do we know and how can we use it?
Gaastra, G. F. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.109733199
Scott, E. L., Assouline, S. G., Vispoel, W., Foley‐Nicpon, M., Ehly, S., & Roberts, M. A. (2020) · doi:10.17077/etd.005362
Turning Toward ADHD - Removing the Persona, and the Shadow You Can Never Quite Pin Down
Johsnon, J. (2026) · PhilPapers (PhilPapers Foundation) · doi:10.5281/zenodo.21285412
Thorburn, C. E. (2026) · Otago University Research Archive (University of Otago) · doi:10.82348/our-archive.00317
Dutta, C. N., Christov-Moore, L., Ombao, H., & Douglas, P. K. (2022) · doi:10.3389/fnhum.2022.938501.s001
Véronneau-Veilleux, F., Robaey, P., Ursino, M., & Nekka, F. (2022) · doi:10.3389/fncom.2022.849323.s001
Efeitos do complexo gênico CHRNA5-CHRNA3-CHRNB4 sobre o TDAH, a cognição e o tabagismo
Polina, E. R. (2014) · Lume (Universidade Federal do Rio Grande do Sul)
Cognition and comorbidity in ADHD: The role of methylphenidate and development
Tamminga, G. H. (2016) · UvA-DARE (University of Amsterdam)
de Azeredo, L. A., Rovaris, D. L., Mota, N. R., Polina, E. R., Marques, F. Z., Contini, V., Vitola, E. S., Belmonte-de-Abreu, P. S., Rohde, L. A., Grevet, E. H., et al. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0739-9
Crianças com TDAH e o uso de tecnologias para auxílio na aprendizagem
Damaceno, G. D. M., Silva, J., & Brandão, F. F. D. F. (2025) · Brazilian Journal of Development · doi:10.34117/bjdv11n6-042
Methylphenidate effects after one-week exposure in adolescente rats
Vieira, S. L. F. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/y0hr-vr76
A subject-specific neurofeedback approach for cognitive enhancement
Escolano Marco, C., & Zafra, J. M. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Niemann, L. S. (2019) · MACAU: Open Access Repository of Kiel University
Metadata
- Authors
- Wang, G.-J., Volkow, N. D., Wigal, T., Kollins, S. H., Newcorn, J. H., Telang, F., Logan, J., Jayne, M., Wong, C. T., Han, H., Fowler, J. S., Zhu, W., & Swanson, J. M.
- Affiliations
- Brookhaven National Laboratory (US)
- National Institutes of Health (US)
- University of California, Irvine (US)
- Duke University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stony Brook University (US)
- Corresponding author
- Wang, Gene-Jack
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e63023
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3655054
- OpenAlex
- W2059137431
- Cited by
- 144
- References
- 29
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 11 · 2022: 13 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 15 · 2016: 10 · 2015: 8 · 2014: 15 · 2013: 5
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Energy (DE‐ACO2‐76CH00016, 76CH00016)
- Orexigen Therapeutics
- Stony Brook University
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (Z01AA000550)
- National Institute of Mental Health (R01MH066961)
- National Center for Research Resources (M01RR010710)
- Biological and Environmental Research
- Brookhaven National Laboratory (DE-ACO2-76CH00016)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- attention deficit hyperactivity disorder, dopamine transporter, methylphenidate, striatum, caudate nucleus, putamen, ventral striatum, treatment efficacy, adult ADHD
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Caudate Nucleus, Cocaine, Female, Humans, Male, Methylphenidate, Putamen, Case-Control Studies, Radiopharmaceuticals, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Young Adult, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.